InspireMD spent a decade proving that a micron mesh sleeve can trap plaque that ordinary carotid stents let escape, then spent less than a year discovering that a new delivery catheter can undo a hard-won United States launch. Premarket approval of CGuard Prime arrived in June of last year and opened the domestic carotid market for the first mesh-covered stent in that indication. The May recall of the longer Prime delivery system, taken in consultation with the Food and Drug Administration, paused that launch and forced withdrawal of the full-year revenue outlook. The implant itself stayed on the market outside the country and was not part of the action. The investment debate is no longer whether MicroNet works in vessels. It is whether a thin-balance-sheet issuer can restore a delivery system, keep hospitals from walking away, and fund the wait.
International demand still argues that physicians want the implant. Mid-year cash and marketable securities sat near $30 million after starting the year above $54 million, which is the arithmetic of a commercial build that never collected the United States revenue it was staffed to produce. A Nasdaq bid-price notice in July put the listing on a clock that runs into mid-January. Management answered the cash drain with a post-quarter workforce cut sized for about $9 million of annual savings and with a commercial leadership reset. Those moves buy time. They do not replace a domestic catheter.
The next several months resolve whether two pending Agency decisions on the original CGuard platform and the shorter Prime eighty-centimeter system can reopen United States procedures before cash and listing pressure force another recap. If those clearances arrive and hospitals treat the recall as a catheter story rather than a stent story, the franchise still has a path back into the procedure room. If either decision slips, or if operators who lived through the controlled launch refuse a second try, the equity is an option on a still-unproven relaunch financed by whoever still answers the phone.